Diabetes patients with dyslipidemia
Conditions
Interventions
5mg Rosuvastatin will be orally administered once daily for 12 months.
10mg Atorvastatin will be orally administered once daily for 12 months.
Sponsors
Fukui Saiseiki Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with diabetes 2) Patients who have been taking 10mg atorvastatin for more than 3 months 3) Patients whose HDL-C levels are less than 50mg/dL 4) Patiens who were recognized the existence of either s-LDL or IDL by Lipofo-AS kit. 5) Patients whose serum Cr levels less than or equql to 2.5mg/dL 6) Patients whose HbA1c levels(NGSP) are less than 10.4%.
Exclusion criteria
Exclusion criteria: 1) Patients whose electrocardiograms at rest obviously showed the finding of myocardial ischemia. 2) Patients whose serum triglyceride levels are more than 400 mg/dL. 3) Patients whose HbA1c levels varied more than 2% within 3 months. 4) Patients who were judged as ineligible by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.The changes in s-LDL,IDL,LDL and HDL after switching. 2.Renoprotective effects of each statin(SCr,eGFR,Cystatin-C,Urinary albumin),HbA1c,CK,muscle spasms of the lower extremities. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.The achievement ratio according to the management target level of LDL-C in JASGL2012 2.Safety | — |
Countries
Japan
Contacts
Public ContactYukihiro Bando
Saiseikai Fukui Hospital internal medicine
Outcome results
None listed